|
Neonatal Intensive Care Drug Manual
|
| bet | 608/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Vancomycin-Continuous
Revision Date : 16-11-2020
|
Approved: TC, KOH
|
Alert
|
S4-High risk medicine.
Antimicrobial Stewardship Team recommends this drug is listed as Restricted.
Continuous infusion regimen optimises achievement of steady state target concentration with fewer dose adjustments and a lower total daily dose in comparison to intermittent regimen.
|
Indication
|
Infections due to susceptible strains of Staphylococci (including MRSA), Streptococci, Enterococci, Diptheroids, Listeria monocytogenes, Actinomyces, Bacillus spp.
|
Action
|
Bactericidal agent which interferes with cell wall synthesis, inhibits RNA synthesis and alters plasma membrane function.
|
Drug Type
|
Glycopeptide antibiotic.
|
Trade Name
|
Vancomycin Sandoz Vycin. DBL Vancomycin Hydrochloride, Vancocin CP, Vancomycin Alphapharm, Vancomycin AN powder for infusion.
|
Presentation
|
Vancomycin hydrochloride 500 mg vial
Vancomycin hydrochloride 1000 mg vial
|
|
|
| |
